Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low - Time to Sell?

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Saturday . The company traded as low as $10.24 and last traded at $10.39, with a volume of 206423 shares trading hands. The stock had previously closed at $10.77.

Analyst Upgrades and Downgrades

Several research firms recently commented on UPB. Piper Sandler began coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an "overweight" rating and a $75.00 target price for the company. JPMorgan Chase & Co. began coverage on Upstream Bio in a research report on Tuesday, November 5th. They set an "overweight" rating and a $38.00 price objective for the company. TD Cowen initiated coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued a "buy" rating on the stock. Finally, William Blair began coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an "outperform" rating for the company.

Upstream Bio Trading Down 3.5 %

The business has a fifty day moving average of $17.55.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The company had revenue of $0.61 million for the quarter, compared to analysts' expectations of $0.83 million. On average, research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

An institutional investor recently bought a new position in Upstream Bio stock. Moody Aldrich Partners LLC bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 74,773 shares of the company's stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned approximately 0.14% of Upstream Bio at the end of the most recent quarter.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.